India's DMPLOI - Jobs & Networking App
Nifty Pharma Index Closes Lower Amid Mixed Sectoral Performance
October 27, 2025: The Nifty Pharma Index ended the session slightly lower at 22,310.40, down 46.95 points (0.21%). Despite early gains, selling pressure in heavyweight stocks pulled the index into negative territory. The sector saw a net negative contribution of -39.58 points, with 11 stocks dragging the index down against 9 gainers.
Top Gainers (Pullers)
Leading the gains, Laurus Labs surged 1.48% to ₹940.15, contributing +14.88 points to the index. Ipca Labs also performed strongly, rising 2.31% to ₹1,298.00, adding +11.33 points.
Other notable contributors included:
Aurobindo Pharma: up 0.89% to ₹1,094.70 (+7.57 points)
Zydus Lifesciences: up 0.89% to ₹1,013.85 (+6.22 points)
Torrent Pharma: up 1.04% to ₹3,754.40 (+4.37 points)
Minor gains were also recorded by Biocon, Dr. Reddy’s Labs, Granules India, and Natco Pharma.
Top Losers (Draggers)
On the downside, Divis Labs was the biggest drag, dropping 1.56% to ₹6,490.00, wiping -36.47 points from the index. Sun Pharma, the sector heavyweight with a 22.3% weightage, fell 0.92% to ₹1,693.60, contributing -15.86 points.
Other major laggards included:
Alkem Labs: down 1.25% to ₹5,475.50 (-10.90 points)
Lupin: down 0.43% to ₹1,922.90 (-6.20 points)
Gland Pharma: down 1.01% to ₹2,248.10 (-5.61 points)
Losses were also noted in Mankind Pharma, Glenmark, Ajanta Pharma, Abbott India, Cipla, and JB Chemicals.
Market Overview
While select mid-cap pharma stocks showed resilience, index heavyweights such as Sun Pharma and Divis Labs weighed on overall performance. The mixed movement across the sector reflects investor caution ahead of upcoming quarterly results and global market cues.
The Nifty Pharma index touched a day high of 22,411.55 and a low of 22,272.35, indicating range-bound trade with a mild negative bias.
